Fenofibrate - Veloxis Pharmaceuticals

Drug Profile

Fenofibrate - Veloxis Pharmaceuticals

Alternative Names: Fenoglide; LCP-FenoChol

Latest Information Update: 07 Apr 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LifeCycle Pharma
  • Developer Veloxis Pharmaceuticals
  • Class Antihyperlipidaemics; Benzophenones; Butyric acids; Fibric acid derivatives; Propionates; Small molecules
  • Mechanism of Action Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperlipidaemia

Most Recent Events

  • 01 Apr 2015 Salix Pharmaceuticals has been acquired by Valeant Pharmaceuticals International
  • 02 Jan 2014 Santarus has been acquired and merged into Salix Pharmaceuticals
  • 22 Dec 2011 Fenofibrate licence in USA transferred from Shore Therapeutics to Santarus ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top